ACADIA Pharmaceuticals Inc (ACAD)

36.31
NASDAQ : Health Care
Prev Close 36.31
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.64 / 49.82
Avg Volume 2.63M
Exchange NASDAQ
Shares Outstanding 113.16M
Market Cap 4.14B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

ACADIA Pharmaceuticals Added To Large-Cap Russell 1000 Market Index

ACADIA Pharmaceuticals Added To Large-Cap Russell 1000 Market Index

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More

Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More

Here are Wednesday's top research calls, including downgrades for Domino's Pizza, McDonald's and Tesla, and an upgrade for Priceline.

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 21, 2016

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 21, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

ACADIA Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference On June 8, 2016

ACADIA Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference On June 8, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

ACADIA Pharmaceuticals (ACAD) Is Today's Storm The Castle Stock

ACADIA Pharmaceuticals (ACAD) Is Today's Storm The Castle Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

'Mad Money' Lightning Round: I'm Sticking With Panera Forever

'Mad Money' Lightning Round: I'm Sticking With Panera Forever

Cramer says MasterCard is fantastic and Medtronic is a great company.

Jim Cramer's 'Mad Money' Recap: These Stocks Have Staying Power

Jim Cramer's 'Mad Money' Recap: These Stocks Have Staying Power

Staying power is underrated by traders but is the lifeblood of long-term investors, Cramer says.

Acadia Pharmaceutical's Nuplazid Pricing Is Good News for Shareholders

Acadia Pharmaceutical's Nuplazid Pricing Is Good News for Shareholders

Acadia's pricing of Nuplazid at $24,000 per year was higher than Wall Street expected and is good news for shareholders.

Acadia (ACAD) Stock Slides in After-Hours Trading on Q1 Financial Results

Acadia (ACAD) Stock Slides in After-Hours Trading on Q1 Financial Results

Acadia (ACAD) stock is down in after-hours trading after reporting first quarter financial results.

ACADIA Pharmaceuticals (ACAD) Lags In Post-Market Trading

ACADIA Pharmaceuticals (ACAD) Lags In Post-Market Trading

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market laggard candidate

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Acadia Drug Approval May Entice Biogen, Teva as Buyers

Acadia Drug Approval May Entice Biogen, Teva as Buyers

Analysts believe that the biotech company could fetch up to $6 billion in a sale since its compound will be the first in a new class of anti-psychotic drugs.

Acadia Pharmaceuticals Stock Has Fallen Too Far Recently

Acadia Pharmaceuticals Stock Has Fallen Too Far Recently

Acadia shares have fallen significantly since the company's Nuplazid drug received FDA approval. Here's why they're worth more.

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 11, 2016

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 11, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher

Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher

A number of factors help explain the less-than-celebratory reaction to the approval of Acadia Pharma's first drug, Nuplazid.

8 Stocks Spiking on Big Volume

8 Stocks Spiking on Big Volume

Here's a technical look at how to trade eight stocks rising on unusual volume recently.

Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More

Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More

Here are Tuesday's top research calls, including downgrades for Acadia, International Paper and Walmart, and an upgrade for Amazon.

Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug

Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug

The FDA approved Nuplazid, a drug used to treat Parkinson's disease psychosis and the related hallucinations and delusions.

ACADIA Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 5, 2016

ACADIA Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 5, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.